Voyager Therapeutics

VYGR77

$5.28arrow_drop_down2.42%-$0.12

VYGR77

$5.28

arrow_drop_down2.42%-$0.12

Performance History

Key Stats
Open	$5.41
Prev. Close	$5.27
EPS	0.66
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

	LOW	HIGH
Day Range	5.28	5.58
52 Week Range	5.19	11.72

Ratios







EPS	0.66

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Voyager Therapeutics (VYGR)

Voyager Therapeutics Inc (VYGR) is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. With a deep understanding of the biology of the central nervous system, Voyager is pioneering a new approach to treating these devastating conditions. The company's innovative gene therapy platform enables the delivery of therapeutic genes directly to the brain, potentially offering a one-time treatment solution. Through strategic partnerships and a robust pipeline of product candidates, Voyager is at the forefront of the gene therapy revolution.

Founded in 2014, Voyager has quickly established itself as a leader in the field. The company's stock price history reflects its steady growth and investor confidence in its groundbreaking therapies. Voyager's commitment to rigorous scientific analysis is evident in its extensive stock analysis, which provides detailed insights into the company's financial performance and future prospects. With a market cap of XX billion, Voyager is well positioned to capitalize on the growing demand for innovative neurological treatments.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
Headquarters: Cambridge
Employees: 125
Exchange: NASDAQ

Keep an eye on Voyager Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Voyager Therapeutics 's (VYGR) price per share?

The current price per share for Voyager Therapeutics (VYGR) is $5.28. The stock has seen a price change of -$0.13 recently, indicating a -2.43% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Voyager Therapeutics (VYGR)?

For Voyager Therapeutics (VYGR), the 52-week high is $11.72, which is 121.97% from the current price. The 52-week low is $5.19, the current price is 1.73% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Voyager Therapeutics (VYGR) a growth stock?

Voyager Therapeutics (VYGR) has shown an average price growth of -7.23% over the past three years. It has received a score of 80 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Voyager Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Voyager Therapeutics (VYGR) stock price performance year to date (YTD)?

As of the latest data, Voyager Therapeutics (VYGR) has a year-to-date price change of -41.33%. Over the past month, the stock has experienced a price change of -31.07%. Over the last three months, the change has been -24.03%. Over the past six months, the figure is -37.51%. Looking at a longer horizon, the five-year price change stands at -63.61%.

help

Is Voyager Therapeutics (VYGR) a profitable company?

Voyager Therapeutics (VYGR) has a net income of $132.33M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 63.13% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -55.95% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $250.01M, although specific revenue growth data is currently not available. The gross profit is $157.84M. Operating income is noted at $122.01M. Furthermore, the EBITDA is $126.46M.

help

What is the market capitalization of Voyager Therapeutics (VYGR)?

Voyager Therapeutics (VYGR) has a market capitalization of $292.79M. The average daily trading volume is 5.28, indicating the stock's liquidity and investor engagement.

News

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

TAU INHIBITORS

ALZHEIMER'S DISEASE

NEURODEGENERATIVE DISEASES

CLINICAL TRIALS

PIPELINE ANALYSIS

Oct 14, 2024

Tau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight

Gene Therapy Market Size to Reach USD 54.39 Billion By 2032 with CAGR of 23.12%, Boosted by Rising Genetic Disorders and Advances in CRISPR Technology

RESTRICTED STOCK UNITS

Jul 23, 2024

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

CALENDAR OF EVENTS

Jun 13, 2024

Voyager Therapeutics to Present at Multiple Virtual Investor Conferences

DIRECTORS AND OFFICERS

Jun 13, 2024